A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

Lupus

Volumn 8, Issue 3, 1999, Pages 181-187

  Van Vollenhoven, R F ^a   Park, J L ^b   Genovese, M C ^b   West, J P ^b   McGuire, J L ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

DHEA; SLE; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PRASTERONE; PREDNISONE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUMBOSACRAL SPINE; MALE; NEPHRITIS; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 0032918390     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847588     Document Type: Article

References (25)

1. Parker LN. Control of adrenal androgen secretion. Endocrin Metab Clin N Am 1991; 20: 401-421.
2. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994; 343: 1479-1481.
3. Daynes RA, Araneo BA. Natural regulators of T-cell lymphokine production in vivo. J Immunother 1992; 12: 174-179.
4. Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of inlerleukin 2 synthesis by helper T cells. Eur J Immunol 1990; 20: 793-802.
5. Daynes RA, Araneo BA, Dowell TA et al. Regulation of murine lymphokine production in vivo III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990; 171: 979-996.
6. Suzuki T, Suzuki N, Daynes RA et al. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991; 61: 202-210.
7. van Vollenhoven RF, McGuire JL. Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases? Cleveland Clinic J of Med 1994; 61: 276-284.
8. van Vollenhoven RF, Engleman EG, McGuire JE. Dehydroepiandrosterone (DHEA) in systemic lupus erythematosus: results of a double-blinded, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826-1831.
9. Liang MH, Socher SA, Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
10. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a Disease Activity Index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
11. Jungers P, Nahoul K, Pelissier C et al. Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 1982; 25: 454-462.
12. Lahita RG, Bradlow HE, Ginzler E et al. Eow plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241-248.
13. Roubinian JR, Talal N, Siiteri PK et al. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979; 22: 1162-1169.
14. 1 mice. J Exp Med 1987; 147: 1568-1583.
15. 1 females of different ages. Arthritis Rheum 1980; 23: 41-48.
16. 1 mice fed dehydroisoandrosterone. J Clin Invest 1985; 75: 2091-2093.
17. 1 mice: lack of an effect on associated immunological abnormalities. Biochimica et Biophysica Acta 1989; 992: 265-271.
18. van Vollenhoven RF, McDevitt HO. Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone. Arthritis Rheum 1992; 35: (Suppl) S207.
19. Lahita RG, Cheng CY, Monder C et al. Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women. J Rheumatol 1992; 19: 447-455.
20. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388-1398.
21. Linker-Israeli M, Bakke AC, Kitridou RC et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-2655.
22. Suzuki T, Suzuki N, Engleman EG et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin and Exper Immunol 1995; 99: 251-255.
23. van Vollenhoven RF, Morabito LM, Engleman EG et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285-289.
24. Hodgson SF. Corticosteroid-induced osteoporosis. Endocrinol Metabol Clin North Am 1990; 19: 95-111.
25. Labrie F, Diamond P, Cusan L et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3498-3505.